Revalesio has begun a Phase IIa trial of RNS60 in patients with relapsing-remitting multiple sclerosis (RRMS or MS). The trial will be conducted by neurologist Dr. Roland Martin, head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. The study will compare measurements of disease activity and progression in patients with RRMS during six months treatment with RNS60. The open label study will enroll 15 patients and evaluate the use of RNS60 by intraven...